| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 77 | 2024 | 20823 | 2.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2024 | 11525 | 1.410 |
Why?
|
| Paclitaxel | 12 | 2024 | 1708 | 1.170 |
Why?
|
| Neoadjuvant Therapy | 16 | 2023 | 2727 | 1.050 |
Why?
|
| Genes, BRCA2 | 6 | 2020 | 618 | 0.900 |
Why?
|
| Breast Neoplasms, Male | 3 | 2020 | 210 | 0.890 |
Why?
|
| BRCA1 Protein | 6 | 2021 | 1149 | 0.810 |
Why?
|
| Piperazines | 9 | 2024 | 2488 | 0.770 |
Why?
|
| BRCA2 Protein | 5 | 2020 | 794 | 0.770 |
Why?
|
| Indazoles | 1 | 2022 | 290 | 0.750 |
Why?
|
| Carboplatin | 4 | 2021 | 801 | 0.710 |
Why?
|
| Camptothecin | 5 | 2023 | 576 | 0.710 |
Why?
|
| Receptor, erbB-2 | 15 | 2022 | 2417 | 0.680 |
Why?
|
| Antineoplastic Agents | 15 | 2021 | 13695 | 0.670 |
Why?
|
| Cisplatin | 4 | 2021 | 1662 | 0.650 |
Why?
|
| Phosphatidylinositol 3-Kinases | 12 | 2024 | 2938 | 0.620 |
Why?
|
| Pyrimidines | 6 | 2024 | 2943 | 0.600 |
Why?
|
| Carbolines | 1 | 2018 | 265 | 0.570 |
Why?
|
| Maytansine | 2 | 2021 | 80 | 0.560 |
Why?
|
| Immunoconjugates | 5 | 2023 | 901 | 0.530 |
Why?
|
| Piperidines | 2 | 2022 | 1602 | 0.530 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2020 | 1100 | 0.500 |
Why?
|
| Breast | 2 | 2020 | 1970 | 0.470 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 7 | 2024 | 890 | 0.420 |
Why?
|
| Neoplasm Staging | 20 | 2021 | 11031 | 0.420 |
Why?
|
| Mastectomy | 9 | 2022 | 1793 | 0.390 |
Why?
|
| Mutation | 16 | 2024 | 29786 | 0.380 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1462 | 0.370 |
Why?
|
| Immunotoxins | 1 | 2010 | 179 | 0.370 |
Why?
|
| Female | 92 | 2024 | 380200 | 0.360 |
Why?
|
| Maximum Tolerated Dose | 5 | 2021 | 892 | 0.360 |
Why?
|
| Anilides | 3 | 2020 | 408 | 0.360 |
Why?
|
| Genes, BRCA1 | 5 | 2018 | 781 | 0.320 |
Why?
|
| Receptors, Estrogen | 7 | 2016 | 2190 | 0.320 |
Why?
|
| Neoplasms | 10 | 2022 | 21693 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2021 | 934 | 0.320 |
Why?
|
| Nitriles | 5 | 2015 | 955 | 0.290 |
Why?
|
| Disease-Free Survival | 10 | 2021 | 6896 | 0.290 |
Why?
|
| Humans | 108 | 2024 | 744376 | 0.280 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2020 | 3480 | 0.280 |
Why?
|
| Benzimidazoles | 3 | 2021 | 850 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2024 | 2504 | 0.250 |
Why?
|
| Lymphedema | 3 | 2019 | 534 | 0.250 |
Why?
|
| Loss of Heterozygosity | 3 | 2016 | 684 | 0.250 |
Why?
|
| Biological Specimen Banks | 2 | 2019 | 711 | 0.240 |
Why?
|
| Neoplasm Metastasis | 13 | 2021 | 4851 | 0.240 |
Why?
|
| Axilla | 4 | 2020 | 595 | 0.230 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 1788 | 0.230 |
Why?
|
| Middle Aged | 45 | 2023 | 213388 | 0.210 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2018 | 721 | 0.210 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4933 | 0.210 |
Why?
|
| Lymph Nodes | 3 | 2020 | 3475 | 0.200 |
Why?
|
| Placebos | 4 | 2019 | 1676 | 0.200 |
Why?
|
| Hormones | 3 | 2021 | 889 | 0.200 |
Why?
|
| Pilot Projects | 3 | 2023 | 8319 | 0.190 |
Why?
|
| Aged | 39 | 2022 | 163284 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2022 | 9240 | 0.190 |
Why?
|
| src Homology Domains | 3 | 2003 | 364 | 0.190 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 8642 | 0.190 |
Why?
|
| Receptors, Progesterone | 3 | 2015 | 1098 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2021 | 5173 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 2 | 2023 | 577 | 0.170 |
Why?
|
| Taxoids | 4 | 2024 | 666 | 0.170 |
Why?
|
| Adult | 36 | 2022 | 214056 | 0.160 |
Why?
|
| Tissue Banks | 1 | 2019 | 184 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2019 | 1524 | 0.160 |
Why?
|
| Pyridines | 3 | 2020 | 2825 | 0.160 |
Why?
|
| Alopecia | 2 | 2020 | 382 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 648 | 0.160 |
Why?
|
| Phosphoproteins | 2 | 1998 | 2441 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 17445 | 0.160 |
Why?
|
| Cryotherapy | 1 | 2019 | 155 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 250 | 0.160 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3135 | 0.160 |
Why?
|
| Lymph Node Excision | 2 | 2015 | 1261 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 1 | 2021 | 498 | 0.150 |
Why?
|
| Second Messenger Systems | 1 | 1998 | 206 | 0.150 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3242 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 9274 | 0.150 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 948 | 0.150 |
Why?
|
| Telemedicine | 3 | 2023 | 2872 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1995 | 437 | 0.140 |
Why?
|
| Phthalazines | 2 | 2020 | 363 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2017 | 624 | 0.140 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 2242 | 0.140 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 77 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2023 | 5077 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 2943 | 0.130 |
Why?
|
| Phosphotyrosine | 1 | 1996 | 457 | 0.130 |
Why?
|
| Receptor, trkA | 1 | 1996 | 164 | 0.130 |
Why?
|
| Antigens, Neoplasm | 5 | 2023 | 1988 | 0.130 |
Why?
|
| Hypothermia, Induced | 1 | 2020 | 752 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2019 | 2110 | 0.130 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 1995 | 440 | 0.120 |
Why?
|
| Treatment Outcome | 19 | 2021 | 63115 | 0.120 |
Why?
|
| Cell Line, Tumor | 10 | 2023 | 16692 | 0.120 |
Why?
|
| Fluorouracil | 2 | 2020 | 1619 | 0.120 |
Why?
|
| Fungal Proteins | 1 | 1998 | 912 | 0.120 |
Why?
|
| Triazoles | 3 | 2015 | 910 | 0.120 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 2924 | 0.120 |
Why?
|
| Schizosaccharomyces | 1 | 1996 | 237 | 0.120 |
Why?
|
| Radiation Oncology | 1 | 2020 | 555 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 547 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2021 | 12025 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2021 | 1142 | 0.120 |
Why?
|
| Prognosis | 8 | 2022 | 29060 | 0.120 |
Why?
|
| Dacarbazine | 1 | 2016 | 566 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 10943 | 0.110 |
Why?
|
| Aromatase Inhibitors | 2 | 2015 | 490 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2020 | 2234 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 1996 | 551 | 0.110 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 113 | 0.110 |
Why?
|
| Muscle Proteins | 2 | 1995 | 1158 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 5 | 2021 | 1602 | 0.110 |
Why?
|
| Sample Size | 1 | 2016 | 845 | 0.110 |
Why?
|
| Radiodermatitis | 1 | 2013 | 60 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 3799 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3556 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 5535 | 0.110 |
Why?
|
| Informed Consent | 1 | 2019 | 995 | 0.110 |
Why?
|
| Photochemotherapy | 1 | 2019 | 807 | 0.110 |
Why?
|
| Stiff-Person Syndrome | 1 | 2012 | 28 | 0.110 |
Why?
|
| Limbic Encephalitis | 1 | 2012 | 34 | 0.110 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 9445 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 578 | 0.110 |
Why?
|
| Patient Preference | 1 | 2019 | 889 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2726 | 0.100 |
Why?
|
| Pedigree | 1 | 2020 | 4642 | 0.100 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 1868 | 0.100 |
Why?
|
| Adipocytes | 2 | 1995 | 1185 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2015 | 8432 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2013 | 415 | 0.090 |
Why?
|
| Genomic Instability | 1 | 2015 | 695 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 4839 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2014 | 826 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2016 | 956 | 0.090 |
Why?
|
| Patient Selection | 2 | 2019 | 4216 | 0.090 |
Why?
|
| Telomere | 1 | 2016 | 910 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2014 | 986 | 0.090 |
Why?
|
| Quinolines | 1 | 2014 | 732 | 0.090 |
Why?
|
| Tamoxifen | 2 | 2023 | 981 | 0.080 |
Why?
|
| Genomics | 3 | 2021 | 5717 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2014 | 1355 | 0.080 |
Why?
|
| Burns | 1 | 2020 | 1815 | 0.080 |
Why?
|
| Phosphatidylinositols | 2 | 2000 | 291 | 0.080 |
Why?
|
| Pandemics | 4 | 2022 | 8386 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 973 | 0.080 |
Why?
|
| Heterozygote | 1 | 2015 | 2804 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 713 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 2638 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3590 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1998 | 2752 | 0.070 |
Why?
|
| 3T3 Cells | 4 | 1996 | 1101 | 0.070 |
Why?
|
| Thiazoles | 1 | 2014 | 1483 | 0.070 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 57776 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 3616 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 4185 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2013 | 1058 | 0.070 |
Why?
|
| Lipoproteins | 2 | 2003 | 878 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2015 | 2038 | 0.070 |
Why?
|
| Anthracyclines | 1 | 2009 | 288 | 0.070 |
Why?
|
| Scalp | 2 | 2020 | 380 | 0.070 |
Why?
|
| Glucose | 2 | 1995 | 4398 | 0.070 |
Why?
|
| Platinum | 2 | 2020 | 233 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 12961 | 0.070 |
Why?
|
| Medical Oncology | 3 | 2022 | 2267 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2000 | 2839 | 0.070 |
Why?
|
| Quinazolines | 1 | 2012 | 1356 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2003 | 2918 | 0.070 |
Why?
|
| Young Adult | 10 | 2021 | 56434 | 0.070 |
Why?
|
| Retreatment | 2 | 2018 | 610 | 0.060 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 399 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 2949 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 1377 | 0.060 |
Why?
|
| Male | 12 | 2021 | 350118 | 0.060 |
Why?
|
| Mammary Glands, Human | 1 | 2005 | 199 | 0.060 |
Why?
|
| Antigens, T-Independent | 1 | 2003 | 21 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.060 |
Why?
|
| Mammaplasty | 4 | 2016 | 1204 | 0.060 |
Why?
|
| Mice | 10 | 2023 | 81202 | 0.060 |
Why?
|
| Signal Transduction | 6 | 2006 | 23406 | 0.060 |
Why?
|
| Disease Management | 3 | 2020 | 2460 | 0.060 |
Why?
|
| Inositol Phosphates | 2 | 2000 | 180 | 0.060 |
Why?
|
| Research Design | 2 | 2016 | 5986 | 0.050 |
Why?
|
| Neutropenia | 2 | 2019 | 895 | 0.050 |
Why?
|
| Cell Membrane | 3 | 1998 | 3749 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2006 | 2050 | 0.050 |
Why?
|
| ROC Curve | 3 | 2018 | 3527 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2023 | 175 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1677 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2012 | 2509 | 0.050 |
Why?
|
| Insulin | 2 | 1995 | 6582 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2016 | 5101 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 644 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 23336 | 0.050 |
Why?
|
| Recurrence | 3 | 2020 | 8340 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 568 | 0.050 |
Why?
|
| Fatigue | 2 | 2022 | 1531 | 0.050 |
Why?
|
| Survival Rate | 3 | 2019 | 12788 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2005 | 3144 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 709 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2018 | 10252 | 0.050 |
Why?
|
| Prospective Studies | 6 | 2022 | 53291 | 0.050 |
Why?
|
| Indoles | 1 | 2009 | 1839 | 0.050 |
Why?
|
| Furans | 1 | 2021 | 194 | 0.050 |
Why?
|
| Ketones | 1 | 2021 | 188 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2019 | 2879 | 0.040 |
Why?
|
| Time Factors | 4 | 2017 | 40077 | 0.040 |
Why?
|
| Animals | 10 | 2023 | 168770 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1998 | 3773 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2013 | 3690 | 0.040 |
Why?
|
| Glucose Transporter Type 4 | 2 | 1995 | 250 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1998 | 378 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2004 | 901 | 0.040 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 1998 | 209 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 847 | 0.040 |
Why?
|
| Amenorrhea | 1 | 2021 | 485 | 0.040 |
Why?
|
| Proteomics | 2 | 2012 | 3638 | 0.040 |
Why?
|
| Genotype | 3 | 2021 | 12952 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2000 | 13814 | 0.040 |
Why?
|
| Blood Proteins | 2 | 2000 | 1124 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2017 | 128 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2016 | 63 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 323 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1837 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6539 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2018 | 496 | 0.030 |
Why?
|
| Half-Life | 1 | 2017 | 661 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2017 | 3914 | 0.030 |
Why?
|
| Fasting | 1 | 2022 | 1592 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 956 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2019 | 539 | 0.030 |
Why?
|
| Cell Survival | 1 | 2005 | 5882 | 0.030 |
Why?
|
| Logistic Models | 3 | 2018 | 13409 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2022 | 77459 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1998 | 1202 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 1995 | 337 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5321 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39052 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2019 | 1063 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1996 | 315 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 1343 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2004 | 2418 | 0.030 |
Why?
|
| Focus Groups | 1 | 2019 | 1321 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 35424 | 0.030 |
Why?
|
| Biological Transport | 2 | 1995 | 2120 | 0.030 |
Why?
|
| Incidence | 3 | 2019 | 20950 | 0.030 |
Why?
|
| Biotechnology | 1 | 1996 | 281 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1591 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2274 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 9957 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 1996 | 563 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 911 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2015 | 290 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 492 | 0.030 |
Why?
|
| Triage | 1 | 2020 | 977 | 0.030 |
Why?
|
| ras Proteins | 1 | 1998 | 1060 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1995 | 625 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1782 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 1996 | 3702 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1995 | 709 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1996 | 1723 | 0.030 |
Why?
|
| Reflex, Abnormal | 1 | 2012 | 85 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 2012 | 129 | 0.030 |
Why?
|
| Radiation Pneumonitis | 1 | 2013 | 104 | 0.030 |
Why?
|
| Spasm | 1 | 2012 | 121 | 0.030 |
Why?
|
| Diarrhea | 1 | 2019 | 1348 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12356 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2000 | 5451 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2308 | 0.030 |
Why?
|
| Cell Movement | 3 | 2013 | 5218 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.030 |
Why?
|
| Vinblastine | 1 | 2013 | 502 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 1995 | 847 | 0.020 |
Why?
|
| Kinetics | 2 | 1998 | 6476 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2017 | 2971 | 0.020 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2012 | 104 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2013 | 323 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 336 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1995 | 970 | 0.020 |
Why?
|
| Fertility | 1 | 2016 | 781 | 0.020 |
Why?
|
| Morpholines | 1 | 2014 | 571 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2023 | 3529 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 1771 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1995 | 1284 | 0.020 |
Why?
|
| Point Mutation | 1 | 1996 | 1624 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 4153 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2016 | 1532 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2014 | 542 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 4666 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 4320 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2003 | 5023 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 769 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 4561 | 0.020 |
Why?
|
| Photography | 1 | 2013 | 520 | 0.020 |
Why?
|
| Precipitin Tests | 2 | 2003 | 829 | 0.020 |
Why?
|
| Mesoderm | 1 | 2013 | 686 | 0.020 |
Why?
|
| Anemia | 1 | 2019 | 1503 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.020 |
Why?
|
| Quality of Life | 2 | 2022 | 12803 | 0.020 |
Why?
|
| Photons | 1 | 2013 | 588 | 0.020 |
Why?
|
| Protein Binding | 2 | 1998 | 9384 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2086 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 1856 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2003 | 7882 | 0.020 |
Why?
|
| Back Pain | 1 | 2012 | 545 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1996 | 2968 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 3689 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2015 | 1533 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3596 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 2183 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2000 | 18111 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3921 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 4751 | 0.020 |
Why?
|
| Gene Expression | 2 | 1996 | 7798 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1996 | 4026 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2015 | 1940 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 3666 | 0.020 |
Why?
|
| Methotrexate | 1 | 2012 | 1728 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10183 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2018 | 5006 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1996 | 2916 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2016 | 0.020 |
Why?
|
| Memory Disorders | 1 | 2012 | 1186 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 2007 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1996 | 494 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 738 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 18034 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 7914 | 0.010 |
Why?
|
| Antibodies | 1 | 2012 | 2460 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2645 | 0.010 |
Why?
|
| Alleles | 1 | 2014 | 6933 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2016 | 9849 | 0.010 |
Why?
|
| Molecular Probe Techniques | 1 | 2003 | 119 | 0.010 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 7722 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 8091 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 7023 | 0.010 |
Why?
|
| United States | 2 | 2022 | 69869 | 0.010 |
Why?
|
| Proteins | 1 | 1996 | 6100 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 3511 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1801 | 0.010 |
Why?
|
| Binding Sites | 2 | 2000 | 6111 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2003 | 548 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 6171 | 0.010 |
Why?
|
| Age Factors | 1 | 2017 | 18373 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 1865 | 0.010 |
Why?
|
| Hydrogen Bonding | 1 | 2000 | 291 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1950 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 4464 | 0.010 |
Why?
|
| Phospholipase C delta | 1 | 1998 | 7 | 0.010 |
Why?
|
| Calorimetry | 1 | 1998 | 126 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 40558 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2003 | 1402 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15221 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 25041 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1995 | 11486 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1998 | 292 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6234 | 0.010 |
Why?
|
| Disease Progression | 1 | 2014 | 13285 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1996 | 46 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2000 | 1247 | 0.010 |
Why?
|
| Integrin alphaV | 1 | 1996 | 55 | 0.010 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1996 | 103 | 0.010 |
Why?
|
| Serum Response Factor | 1 | 1996 | 81 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 1996 | 120 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3873 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 1996 | 182 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 1802 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1995 | 158 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 2256 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2000 | 2012 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2013 | 12720 | 0.010 |
Why?
|
| rac GTP-Binding Proteins | 1 | 1995 | 164 | 0.010 |
Why?
|
| Androstadienes | 1 | 1995 | 345 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1998 | 871 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 1409 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1998 | 1728 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1995 | 452 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1996 | 794 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1998 | 3130 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 2475 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2000 | 1809 | 0.010 |
Why?
|
| Ligands | 1 | 1998 | 3282 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15295 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20130 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1996 | 1741 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1996 | 2455 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 6621 | 0.000 |
Why?
|
| Risk Factors | 1 | 2013 | 72295 | 0.000 |
Why?
|
| Brain | 1 | 2012 | 26386 | 0.000 |
Why?
|
| Rats | 1 | 1998 | 24252 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1996 | 5857 | 0.000 |
Why?
|
| Apoptosis | 1 | 1996 | 9726 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1996 | 9647 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1996 | 12073 | 0.000 |
Why?
|